Zongertinib for advanced cancers with HER2 changes
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental pill called zongertinib for people with different types of advanced solid tumors that have a specific genetic change called HER2. It's a treatment option when other therapies haven't worked, and it may help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer must be solid (not blood cancer) and advanced—either spread or not removable by surgery.
- Your tumor must test positive for HER2 (a protein that helps cancer grow) or have a HER2 gene change.
- You must have tried at least one previous treatment for your cancer, and it must have gotten worse.
- You must have a tissue sample from your tumor available for testing.
- You must be able to care for yourself (up and about, though not necessarily fully active).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
This trial tests a new drug called zongertinib combined with chemotherapy, with or without pembrolizumab (an immunotherapy), for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. The goal is to see how safe and well-tolerated the combination is.
This study tests a new pill (zongertinib) combined with fulvestrant (an injection) for people with advanced breast cancer that has a HER2 mutation. The combination may help stop or slow the cancer growth.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
This Phase 1 study tests ZV0203, a new investigational treatment, in people with HER2-positive advanced or metastatic solid tumors that cannot be removed and have not responded to standard treatment. The goal is to find a safe dose and see how the disease responds.
Hear when a new Solid Tumours trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.